Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
International Journal of Molecular Sciences|February 26, 2022
Dysregulation of S-adenosylmethionine Metabolism in Nonalcoholic Steatohepatitis Leads to Polyamine Flux and Oxidative StressConnor Quinn, Mario C Rico, Carmen Merali, et al.Neuropsychologia|October 11, 2016
Learning and retrieving holistic and componential visual-verbal associations in reading and object namingConnor Quinn, J S H Taylor, Matthew H DavisObesity (Silver Spring, Md.)|October 18, 2024
Sustained caloric restriction potentiates insulin action by activating prostacyclin synthaseCarmen Merali, Connor Quinn, Kim M Huffman, et al.Science Translational Medicine|September 27, 2023
Secreted folate receptor γ drives fibrogenesis in metabolic dysfunction-associated steatohepatitis by amplifying TGFβ signaling in hepatic stellate cellsConnor Quinn, Mario C Rico, Carmen Merali, et al.Nature Structural & Molecular Biology|January 4, 2024
Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small moleculesChristopher M Hickey, Katherine M Digianantonio, Kurt Zimmermann, et al.Nature Communications|November 10, 2022
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancersJennifer Cantley, Xiaofen Ye, Emma Rousseau, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2024
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer ModelsSheryl M Gough, John J Flanagan, Jessica Teh, et al.Journal of Medicinal Chemistry|January 5, 2024
PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor ModelsMichael Berlin, Jennifer Cantley, Mark Bookbinder, et al.Pageof 1